Avanafil: Phase III started

Vivus began the open-label, U.S. Phase III safety trial (TA-314) to evaluate 50-200 mg oral avanafil for up to 52 weeks in about 600 patients who completed the 12-week REVIVE (TA-301) or REVIVE-Diabet...